Quadriga BioSciences is thrilled to announce that the first subject has been dosed in their groundbreaking Phase 2 clinical study of QBS10072S (QBS72S), a potential game-changing targeted therapy for the treatment of brain metastases of breast cancers. This marks a major milestone in Quadriga’s mission to bring life-saving treatments to those affected by cancer.
Brain metastases represent a critical unmet need in oncology, as current treatments are inadequate. At Quadriga BioSciences, we are excited to be exploring the potential of QBS72S, a powerful therapy that can cross the blood brain barrier and target cancer cells, to improve outcomes for these patients. Our team is eager to work together with our colleagues at Stanford Medicine to investigate this further.
When breast cancer metastasizes to the brain, current treatment options are often ineffective due to the difficulty of delivering therapeutic agents across the blood brain barrier (BBB). As a result, finding new and effective treatments for breast cancer metastasized to the brain remains a challenge.
Breast cancer brain metastases can be devastating and have a major impact on quality of life, yet current treatments are limited. At Stanford Medicine, Professor of Neurosurgery and Co-Director of the Stanford Brain Tumor Center, Melanie Hayden Gephart, M.D., is leading a Phase 2 clinical study to investigate the potential of the promising compound QBS72S. This cutting edge compound has shown promise in preclinical studies due to its targeted action and could offer new hope to those affected by breast cancer brain metastases.
The INSIGhT study at the Dana-Farber Cancer Institute is currently investigating the potential of QBS72S as a treatment for glioblastoma. The two Phase 2 studies, funded by Small Business Innovation Grants (SBIR) and the California Breast Cancer Research Program, are exploring the efficacy of the drug for both breast and brain cancer. If successful, the results could lead to a breakthrough in cancer treatment.
QBS72S is an innovative chemotherapeutic agent that brings hope in the fight against aggressive cancers. This novel drug mimics an aromatic amino acid, allowing it to be transported across the blood brain barrier (BBB) and into cancer cells by the amino acid transporter LAT1.
QBS72S targets rapidly growing cancer cells, causing double-stranded DNA breaks and thus inducing cell death. As LAT1 expression is commonly linked to poor prognoses, this therapeutic offers a new ray of hope in the battle against cancer.
About the Study
QBS72S, a potential breakthrough therapeutic for brain metastases from breast cancer, is being evaluated in a Phase 2 open-label clinical trial. Up to 35 patients will be recruited to assess the safety, tolerability and efficacy of this treatment.
The primary objective is to determine preliminary efficacy through overall response rate, while secondary endpoints include measurement of progression free survival, overall survival, duration of response, and adverse events. With promising results, this treatment could bring hope to those who are living with this devastating disease.
About Quadriga BioSciences
At Quadriga BioSciences, we are on a mission to revolutionize cancer treatment with our groundbreaking new drug, QBS10072S (QBS72S). This revolutionary chemotherapeutic agent is designed to cross the blood brain barrier (BBB) and target multiple types of cancer cells that overexpress the nutrient-intake transporter LAT1. We are committed to creating a safer and more effective treatment for those battling cancer and to ensure that they have access to the best possible care.